A61K

(21) Int. Application Number: PCT/US96/17677
(22) Int. Filing Date: 15 November 1996 (15.11.96)
(30) Priority Data: 08/560,685 20 November 1995 (20.11.95) US

(71) Applicants: GUILFORD PHARMACEUTICALS INC. [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US). JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; Suite 72-100, 2024 East Monument, Baltimore, MD 21205 (US).

(72) Inventors: STEINER, Joseph, P.; 988 Sugar Maple Street, Hampstead, MD 21074 (US). HAMILTON, Gregory, S.; 6501 Frederick Road, Catonsville, MD 21228 (US). SNYDER, Solomon, H.; Johns Hopkins Medical School, 725 N. Wolfe Street, Baltimore, MD 21205-2185 (US).

(74) Agent: NATH, Gary, M.; Nath & Associates, Suite 750, 1835 K Street, N.W., Washington, DC 20006-1203 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims.

(51) International Patent Classification 6: A61K 38/13, 38/00, C12P 21/00

A1

(11) Int. Publication Number: WO 97/18828
(43) Int. Publication Date: 29 May 1997 (29.05.97)

(54) Title: INHIBITORS OF CYCLOPHILIN ROTAMASE ACTIVITY

(57) Abstract

This invention relates to the method of using neurotrophic cyclophilin inhibitor compounds having an affinity for cyclophilin-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

(21) Int. Application Number: PCT/JP96/03333
(22) Int. Filing Date: 14 November 1996 (14.11.96)
(30) Priority Data: 7/322402 17 November 1995 (17.11.95) JP

(71) Applicant *(for all designated States except US)*: HOECHST PHARMACEUTICALS & CHEMICALS K.K. [JP/JP]; 17-51, Akasaka 2-chome, Minato-ku, Tokyo 107 (JP).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: SHIMURA, Takesada [JP/JP]; Nippon Hoechst Marion Roussel Ltd., Preclinical Development Laboratories, 3-2, Minamidai 1-chome, Kawagoe-shi, Saitama 350-11 (JP). TORIYAMA, Satsuki [JP/JP]; Nippon Hoechst Marion Roussel Ltd., Preclinical Development Laboratories, 3-2, Minamidai 1-chome, Kawagoe-shi, Saitama 350-11 (JP).

(74) Agents: TAKAGI, Chiyoshi et al.; Kojimachi Koyo Building, 10, Kojimachi 1-chome, Chiyoda-ku, Tokyo 102 (JP).

(81) Designated States: AU, CA, CN, HU, KR, MX, NO, NZ, RU, UA, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, NL, PT, SE).

Published
With international search report.

(51) International Patent Classification 6: A61K 38/18, 47/32, A61F 2/28, A61B 17/56, A61M 37/00


A1

(11) Int. Publication Number: WO 97/18829
(43) Int. Publication Date: 29 May 1997 (29.05.97)

(54) Title: CARTILAGE/BONE INDUCING MATERIALS FOR REPARATION

(57) Abstract

Cartilage/bone inducing materials for reparation which contain a bone inducer and polyoxyethylene polyoxypropylene glycol. In a particularly preferable example, the molecular weight of the polypropylene glycol constituting the polyoxyethylene polyoxypropylene glycol falls within the range of from about 1,500 to 4,000, the weight ratio of the ethylene oxide units falls within the range of from about 40 to 80 %/molecule, and the concentration of the polyoxyethylene polyoxypropylene glycol is about 10 to 50 % based on the aqueous solution. These materials are used in the cartilage/bone induction method without requiring any operation. Because of being composed of a bone inducer and a carrier which is easily absorbed *in vivo*, highly compatible with the bone inducer and undergoes reversible sol-gel change depending on the temperature, they can be highly applicable to fracture and bone-defective sites and thus exert excellent therapeutic effects.



a ... Molecular weight of polypropylene glycol

b ... Ethylene oxide content in all molecules (wt. %)